104 related articles for article (PubMed ID: 1694165)
1. Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites.
Kunimoto S; Komuro K; Nosaka C; Tsuchiya T; Fukatsu S; Takeuchi T
J Antibiot (Tokyo); 1990 May; 43(5):556-65. PubMed ID: 1694165
[TBL] [Abstract][Full Text] [Related]
2. Antitumour activity of new semi-synthetic anthracyclines containing fluorotalopyranose.
Umezawa K; Takeuchi T; Komuro K; Nosaka C; Kunimoto S; Tsuchiya T; Takagi Y; Umezawa S; Umezawa H
Drugs Exp Clin Res; 1988; 14(7):429-34. PubMed ID: 3240703
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and metabolism of a new anthracycline-containing fluorine (ME2303) in Lewis lung carcinoma-bearing mice.
Iigo M; Hoshi A; Kadosawa H; Fujigaki M
Jpn J Cancer Res; 1991 Nov; 82(11):1317-21. PubMed ID: 1752788
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity of 7-O-[2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)-alpha-L-talopyranosyl]- daunomycinone and -adriamycinone.
Nakai K; Takagi Y; Tsuchiya T
Carbohydr Res; 1999 Mar; 316(1-4):47-57. PubMed ID: 10420587
[TBL] [Abstract][Full Text] [Related]
5. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
6. 3'-Hydroxyesorubicin. Synthesis and antitumor activity.
Priebe W; Neamati N; Perez-Soler R
J Antibiot (Tokyo); 1990 Jul; 43(7):838-46. PubMed ID: 2387778
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor activity of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl) daunomycinone derivatives modified at C-3' or C-4'.
Takagi Y; Kobayashi N; Chang MS; Lim GJ; Tsuchiya T
Carbohydr Res; 1998 Feb; 307(3-4):217-32. PubMed ID: 9675364
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of antitumor-active 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)-daunomycinone and -adriamycinone.
Ok K; Takagi Y; Tsuchiya T; Umezawa S; Umezawa H
Carbohydr Res; 1987 Nov; 169():69-81. PubMed ID: 3427590
[TBL] [Abstract][Full Text] [Related]
9. Syntheses and antitumor activities of 7-O-(3-amino-2,3,6-trideoxy-2-fluoro-alpha-L-talopyranosyl)daunomvcinone and -adriamycinone.
Takagi Y; Park H; Tsuchiya T; Umezawa S; Takeuchi T; Komuro K; Nosaka C
J Antibiot (Tokyo); 1989 Aug; 42(8):1315-7. PubMed ID: 2759914
[No Abstract] [Full Text] [Related]
10. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.
Szmigielska-Kaplon A; Ciesielska E; Szmigiero L; Robak T
Eur J Haematol; 2002 Jun; 68(6):370-5. PubMed ID: 12225395
[TBL] [Abstract][Full Text] [Related]
11. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
[TBL] [Abstract][Full Text] [Related]
12. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
13. Syntheses and antitumor activities of 7-O-(6-deoxy-2-O-methyl-alpha-L-talopyranosyl)-daunomycinone and -adriamycinone.
Takagi Y; Kobayashi N; Tsuchiya T; Umezawa S; Takeuchi T; Komuro K; Nosaka C
J Antibiot (Tokyo); 1989 Aug; 42(8):1318-20. PubMed ID: 2759915
[No Abstract] [Full Text] [Related]
14. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
15. Sonodynamically-induced cell damage with fluorinated anthracycline derivative, FAD104.
Yumita N; Umemura S; Kaneuchi M; Okano Y; Magario N; Ishizaki M; Shimizu K; Sano Y; Umemura K; Nishigaki R
Cancer Lett; 1998 Mar; 125(1-2):209-14. PubMed ID: 9566717
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline resistance in murine leukemic P388 cells. Role of drug efflux and glutathione related enzymes.
Nair S; Singh SV; Samy TS; Krishan A
Biochem Pharmacol; 1990 Feb; 39(4):723-8. PubMed ID: 2306280
[TBL] [Abstract][Full Text] [Related]
17. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline glycosides of 2,6-dideoxy-2-fluoro-alpha-L-talopyranose.
Horton D; Khare A
Carbohydr Res; 2006 Nov; 341(16):2631-40. PubMed ID: 17022957
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia.
Sadzuka Y; Sugiyama T; Sawanishi H; Miyamoto K
Cancer Lett; 1999 Apr; 138(1-2):5-11. PubMed ID: 10378767
[TBL] [Abstract][Full Text] [Related]
20. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
